CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 131 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2017. The put-call ratio across all filers is 1.26 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $24,000 | -17.2% | 10,350 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $29,000 | +61.1% | 10,350 | +36.2% | 0.00% | 0.0% |
| Q3 2017 | $18,000 | -5.3% | 7,600 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $19,000 | -29.6% | 7,600 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $27,000 | -87.7% | 7,600 | -3.2% | 0.00% | -92.9% |
| Q1 2015 | $219,000 | -13.4% | 7,854 | +9.9% | 0.01% | -41.7% |
| Q3 2013 | $253,000 | – | 7,149 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| KLP Enterprises, LLC | 6,865,000 | $3,096,000 | 100.00% |
| TSP Capital Management Group, LLC | 698,674 | $1,549,000 | 0.79% |
| Meditor Group Ltd | 6,312,700 | $2,847,000 | 0.61% |
| Telemetry Investments, L.L.C. | 186,200 | $84,000 | 0.04% |
| GSA CAPITAL PARTNERS LLP | 1,270,500 | $573,000 | 0.03% |
| Benchmark Capital Advisors | 53,400 | $24,000 | 0.02% |
| BOENNING & SCATTERGOOD, INC. | 80,150 | $36,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 80,000 | $36,000 | 0.01% |
| Centiva Capital, LP | 121,720 | $55,000 | 0.01% |
| Overbrook Management Corp | 48,611 | $22,000 | 0.00% |